Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.
Protein

Basic phospholipase A2 homolog bothropstoxin-1

Gene
N/A
Organism
Bothrops jararacussu (Jararacussu)
Status
Reviewed-Annotation score: Annotation score: 5 out of 5-Experimental evidence at protein leveli

Functioni

Snake venom phospholipase A2 homolog that lacks enzymatic activity. In vivo, induces muscle necrosis, accompanied by polymorphonuclear cell infiltration, and edema in the mouse paw. Damages artificial and myoblast membranes by a calcium-independent mechanism. Has bactericidal activity.7 Publications

GO - Molecular functioni

GO - Biological processi

Complete GO annotation...

Keywords - Molecular functioni

Antibiotic, Antimicrobial, Myotoxin, Toxin

Names & Taxonomyi

Protein namesi
Recommended name:
Basic phospholipase A2 homolog bothropstoxin-1
Short name:
svPLA2 homolog
Alternative name(s):
BOJU-I
Bothropstoxin I
Short name:
BthTx-I
Short name:
BtxtxI
Myotoxic phospholipase A2-like
Phospholipase A2 homolog 1
OrganismiBothrops jararacussu (Jararacussu)
Taxonomic identifieri8726 [NCBI]
Taxonomic lineageiEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiLepidosauriaSquamataBifurcataUnidentataEpisquamataToxicoferaSerpentesColubroideaViperidaeCrotalinaeBothrops

Subcellular locationi

GO - Cellular componenti

Complete GO annotation...

Keywords - Cellular componenti

Secreted

Pathology & Biotechi

Toxic dosei

LD50 is 7.5-8.5 mg/kg by intraperitoneal injection and 4.8 mg/kg by intravenous injection into mice.2 Publications

Mutagenesis

Feature keyPosition(s)DescriptionActionsGraphical viewLength
Mutagenesisi23K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi31K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi51K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi52P → A: Important decrease in myotoxicity when injected into mice. Decrease in membrane permeabilization of cultured myoblasts. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Increase in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi53K → A: No change in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. No change in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi54D → A: No change in myoblast membrane permeabilizing activities. 1 Publication1
Mutagenesisi58R → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi61Y → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi63H → Q: No change in myotoxic activities. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent membrane-damaging activities. Shows no hydrolytic activity. 3 Publications1
Mutagenesisi64K → D: No change in myotoxic activities. No change in calcium-independent membrane-damaging and myotoxic activities. Shows no hydrolytic activity. 1 Publication1
Mutagenesisi68K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi69K → A: Increase in myotoxicity when injected into mice. Increase in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi71T → KR: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1
Mutagenesisi87K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi93E → G: No change in myotoxicity when injected into mice. Important decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi99K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi106K → A: Increase in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi118T → A: No change in myoblast membrane permeabilizing activities. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi120N → A: No change in myotoxicity when injected into mice. Increase in myoblast membrane permeabilizing activities. No change in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi121K → A: No change in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications1
Mutagenesisi122K → A: No change in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 2 Publications1
Mutagenesisi123Y → A: Important decrease in myotoxicity when injected into mice. Important decrease in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications1
Mutagenesisi123Y → W: No change (PubMed:17346668) or important decrease (PubMed:12079495) in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Important increase in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications1
Mutagenesisi124R → A: Important decrease in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications1
Mutagenesisi125Y → A: Important decrease in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 2 Publications1
Mutagenesisi125Y → W: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 2 Publications1
Mutagenesisi126H → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi127L → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 1 Publication1
Mutagenesisi128K → A: Important decrease in myotoxicity when injected into mice. Important decrease in myoblast membrane permeabilizing activities. Important decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. Shows no hydrolytic activity. 4 Publications1
Mutagenesisi130F → A: Important decrease in myotoxicity when injected into mice. Decrease in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. Important decrease in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications1
Mutagenesisi130F → W: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. Decrease (PubMed:17346668) or important decrease (PubMed:12079495) in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications1
Mutagenesisi132K → A: No change in myotoxicity when injected into mice. Important decrease in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 2 Publications1
Mutagenesisi133K → A: No change in myotoxicity when injected into mice. No change in myoblast membrane permeabilizing activities. Decrease in bactericidal activity. No change in calcium-independent damaging activity against EYPC:DPPG liposomes. No change in calcium-independent damaging activity against EYPC:DMPA liposomes. 3 Publications1

PTM / Processingi

Molecule processing

Feature keyPosition(s)DescriptionActionsGraphical viewLength
Signal peptidei1 – 163 PublicationsAdd BLAST16
ChainiPRO_000016162217 – 137Basic phospholipase A2 homolog bothropstoxin-1Add BLAST121

Amino acid modifications

Feature keyPosition(s)DescriptionActionsGraphical viewLength
Disulfide bondi42 ↔ 131Combined sources3 Publications
Disulfide bondi44 ↔ 60Combined sources3 Publications
Disulfide bondi59 ↔ 111Combined sources3 Publications
Disulfide bondi65 ↔ 137Combined sources3 Publications
Disulfide bondi66 ↔ 104Combined sources3 Publications
Disulfide bondi73 ↔ 97Combined sources3 Publications
Disulfide bondi91 ↔ 102

Keywords - PTMi

Disulfide bond

Expressioni

Tissue specificityi

Expressed by the venom gland.

Interactioni

Subunit structurei

Homodimer; non-covalently linked.3 Publications

Structurei

Secondary structure

1137
Legend: HelixTurnBeta strandPDB Structure known for this area
Show more details
Feature keyPosition(s)DescriptionActionsGraphical viewLength
Helixi18 – 29Combined sources12
Helixi33 – 37Combined sources5
Beta strandi38 – 40Combined sources3
Turni41 – 43Combined sources3
Beta strandi44 – 47Combined sources4
Helixi55 – 67Combined sources13
Turni75 – 77Combined sources3
Beta strandi82 – 85Combined sources4
Beta strandi88 – 91Combined sources4
Helixi96 – 114Combined sources19
Helixi116 – 118Combined sources3
Helixi121 – 123Combined sources3
Helixi128 – 130Combined sources3

3D structure databases

Select the link destinations:
PDBei
RCSB PDBi
PDBji
Links Updated
PDB entryMethodResolution (Å)ChainPositionsPDBsum
2H8IX-ray1.90A/B17-137[»]
3CXIX-ray1.83A/B17-137[»]
3HZDX-ray1.91A/B17-137[»]
3HZWX-ray2.28A/B17-127[»]
3I03X-ray1.48A17-137[»]
3I3HX-ray2.17A/B17-137[»]
3I3IX-ray1.82A17-137[»]
3IQ3X-ray1.55A/B17-137[»]
4K06X-ray2.08A/B17-137[»]
4K09X-ray2.11A/B17-135[»]
4WTBX-ray2.16A/B17-137[»]
ProteinModelPortaliQ90249.
SMRiQ90249.
ModBaseiSearch...
MobiDBiSearch...

Miscellaneous databases

EvolutionaryTraceiQ90249.

Family & Domainsi

Sequence similaritiesi

Keywords - Domaini

Signal

Phylogenomic databases

HOVERGENiHBG008137.

Family and domain databases

CDDicd00125. PLA2c. 1 hit.
Gene3Di1.20.90.10. 1 hit.
InterProiIPR001211. PLipase_A2.
IPR033112. PLipase_A2_Asp_AS.
IPR016090. PLipase_A2_dom.
IPR033113. PLipase_A2_His_AS.
[Graphical view]
PANTHERiPTHR11716. PTHR11716. 1 hit.
PfamiPF00068. Phospholip_A2_1. 1 hit.
[Graphical view]
PRINTSiPR00389. PHPHLIPASEA2.
SMARTiSM00085. PA2c. 1 hit.
[Graphical view]
SUPFAMiSSF48619. SSF48619. 1 hit.
PROSITEiPS00119. PA2_ASP. 1 hit.
PS00118. PA2_HIS. 1 hit.
[Graphical view]

Sequencei

Sequence statusi: Complete.

Sequence processingi: The displayed sequence is further processed into a mature form.

Q90249-1 [UniParc]FASTAAdd to basket

« Hide

        10         20         30         40         50
MRTLWIMAVL LVGVEGSLFE LGKMILQETG KNPAKSYGAY GCNCGVLGRG
60 70 80 90 100
KPKDATDRCC YVHKCCYKKL TGCDPKKDRY SYSWKDKTIV CGENNPCLKE
110 120 130
LCECDKAVAI CLRENLGTYN KKYRYHLKPF CKKADPC
Length:137
Mass (Da):15,497
Last modified:July 22, 2008 - v3
Checksum:i7BE006BABC4DFC39
GO

Experimental Info

Feature keyPosition(s)DescriptionActionsGraphical viewLength
Sequence conflicti23K → H AA sequence (PubMed:3176051).Curated1
Sequence conflicti74D → N AA sequence (PubMed:8427634).Curated1

Natural variant

Feature keyPosition(s)DescriptionActionsGraphical viewLength
Natural varianti19F → L.1
Natural varianti37Y → H.1
Natural varianti136P → A.1

Sequence databases

Select the link destinations:
EMBLi
GenBanki
DDBJi
Links Updated
AY185200 mRNA. Translation: AAO27453.1.
AY299391 mRNA. Translation: AAP57527.1.
X78599 mRNA. Translation: CAA55334.2.
PIRiA30823.
PC4024.

Cross-referencesi

Sequence databases

Select the link destinations:
EMBLi
GenBanki
DDBJi
Links Updated
AY185200 mRNA. Translation: AAO27453.1.
AY299391 mRNA. Translation: AAP57527.1.
X78599 mRNA. Translation: CAA55334.2.
PIRiA30823.
PC4024.

3D structure databases

Select the link destinations:
PDBei
RCSB PDBi
PDBji
Links Updated
PDB entryMethodResolution (Å)ChainPositionsPDBsum
2H8IX-ray1.90A/B17-137[»]
3CXIX-ray1.83A/B17-137[»]
3HZDX-ray1.91A/B17-137[»]
3HZWX-ray2.28A/B17-127[»]
3I03X-ray1.48A17-137[»]
3I3HX-ray2.17A/B17-137[»]
3I3IX-ray1.82A17-137[»]
3IQ3X-ray1.55A/B17-137[»]
4K06X-ray2.08A/B17-137[»]
4K09X-ray2.11A/B17-135[»]
4WTBX-ray2.16A/B17-137[»]
ProteinModelPortaliQ90249.
SMRiQ90249.
ModBaseiSearch...
MobiDBiSearch...

Protocols and materials databases

Structural Biology KnowledgebaseSearch...

Phylogenomic databases

HOVERGENiHBG008137.

Miscellaneous databases

EvolutionaryTraceiQ90249.

Family and domain databases

CDDicd00125. PLA2c. 1 hit.
Gene3Di1.20.90.10. 1 hit.
InterProiIPR001211. PLipase_A2.
IPR033112. PLipase_A2_Asp_AS.
IPR016090. PLipase_A2_dom.
IPR033113. PLipase_A2_His_AS.
[Graphical view]
PANTHERiPTHR11716. PTHR11716. 1 hit.
PfamiPF00068. Phospholip_A2_1. 1 hit.
[Graphical view]
PRINTSiPR00389. PHPHLIPASEA2.
SMARTiSM00085. PA2c. 1 hit.
[Graphical view]
SUPFAMiSSF48619. SSF48619. 1 hit.
PROSITEiPS00119. PA2_ASP. 1 hit.
PS00118. PA2_HIS. 1 hit.
[Graphical view]
ProtoNetiSearch...

Entry informationi

Entry nameiPA2B1_BOTJR
AccessioniPrimary (citable) accession number: Q90249
Secondary accession number(s): Q7LZ25, Q804D7
Entry historyi
Integrated into UniProtKB/Swiss-Prot: December 5, 2001
Last sequence update: July 22, 2008
Last modified: November 30, 2016
This is version 98 of the entry and version 3 of the sequence. [Complete history]
Entry statusiReviewed (UniProtKB/Swiss-Prot)
Annotation programChordata Protein Annotation Program
Annotation programAnimal Toxin Annotation Program

Miscellaneousi

Caution

Does not bind calcium as one of the calcium-binding ligands is lost (Asp->Lys in position 64, which corresponds to 'Lys-49' in the current nomenclature). However, the hydrolytic activity is not restored by the mutant containing an Asp-64, indicating that other residues play a key role in hydrolytic activity.Curated

Keywords - Technical termi

3D-structure, Direct protein sequencing

Documents

  1. PDB cross-references
    Index of Protein Data Bank (PDB) cross-references
  2. SIMILARITY comments
    Index of protein domains and families

Similar proteinsi

Links to similar proteins from the UniProt Reference Clusters (UniRef) at 100%, 90% and 50% sequence identity:
100%UniRef100 combines identical sequences and sub-fragments with 11 or more residues from any organism into one UniRef entry.
90%UniRef90 is built by clustering UniRef100 sequences that have at least 90% sequence identity to, and 80% overlap with, the longest sequence (a.k.a seed sequence).
50%UniRef50 is built by clustering UniRef90 seed sequences that have at least 50% sequence identity to, and 80% overlap with, the longest sequence in the cluster.